ImmunityBio, Inc.
IBRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2 | $3 | $2 | $2 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $1 | $1 | $1 | $1 |
| Enterprise Value | $2 | $3 | $3 | $3 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 2,270.6% | 159.2% | -74.3% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,793.4% | -76,955.5% | -146,617.1% | -34,341.8% |
| Net Income | -$0 | -$1 | -$0 | -$0 |
| % Margin | -2,804.8% | -93,761.4% | -173,569.6% | -37,129.6% |
| EPS Diluted | -0.62 | -1.15 | -1.04 | -0.89 |
| % Growth | 46.1% | -10.6% | -16.9% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |